Last updated: 10/26/2026 10:40:20

A study of BOS-580 in obese subjects at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH) with an extension

GSK study ID
301182
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 2a, randomized, blinded, placebo-controlled study of BOS-580 in obese subjects at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH) with a single arm open-label extension
Trial description: This is a randomized, blinded, placebo-controlled study of Efimosfermin in obese participants at risk for, or with biopsy-confirmed, nonalcoholic steatohepatitis (NASH), with a single arm open-label extension. It includes Parts A, B, C and D.
Primary purpose:
Treatment
Trial design:
Parallel Assignment
Masking:
Double (Participant, Investigator)
Allocation:
Randomized
Primary outcomes:

Part A: Number of participants with treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TESAEs)

Timeframe: Up to Week 16

Part A: Change from Baseline (CFB) in systolic blood pressure (SBP) and diastolic blood pressure (DBP)

Timeframe: Baseline (Pre-dose on Day 1) and at Week 12

Part A: Change from Baseline in heart rate

Timeframe: Baseline (Pre-dose on Day 1) and at Week 12

Part B: Number of participants with TEAEs and TESAEs

Timeframe: Up to Week 28

Part B: Change from Baseline in systolic blood pressure and diastolic blood pressure

Timeframe: Baseline (Pre-dose on Day 1) and at Week 24

Part B: Change from Baseline in heart rate

Timeframe: Baseline (Pre-dose on Day 1) and at Week 24

Part C: Number of participants with TEAEs and TESAEs

Timeframe: Up to 28 weeks (Study Weeks 28 to 56)

Part C: Change from Baseline in systolic blood pressure and diastolic blood pressure

Timeframe: Baseline (Pre-dose on Day 1) and at study Week 56

Part C: Change from Baseline in heart rate

Timeframe: Baseline (Pre-dose on Day 1) and at Study Week 56

Part D: Number of participants with TEAEs and TESAEs

Timeframe: Up to Week 52

Part D: Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 36

Timeframe: Baseline (Pre-dose on Day 1) and at Week 36

Part D: Change from Baseline in systolic blood pressure and diastolic blood pressure at Week 48

Timeframe: Baseline (Pre-dose on Day 1) and at Week 48

Part D: Change from Baseline in heart rate at Week 36

Timeframe: Baseline (Pre-dose on Day 1) and at Week 36

Part D: Change from Baseline in heart rate at Week 48

Timeframe: Baseline (Pre-dose on Day 1) and Week 48

Part A: Number of participants with Grade 3 and Grade 4 hematologic abnormalities according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)

Timeframe: At Week 12

Part A: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities according to NCI-CTCAE

Timeframe: At Week 12

Part B: Number of participants with Grade 3 and Grade 4 hematologic abnormalities according to NCI-CTCAE

Timeframe: At Week 24

Part B: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities according to NCI-CTCAE

Timeframe: At Week 24

Part C: Number of participants with Grade 3 and Grade 4 hematologic abnormalities according to NCI-CTCAE

Timeframe: At Study Week 56

Part C: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities according to NCI-CTCAE

Timeframe: At Study Week 56

Part D: Number of participants with Grade 3 and Grade 4 hematologic abnormalities at Week 36 according to NCI-CTCAE

Timeframe: At Week 36

Part D: Number of participants with Grade 3 and Grade 4 hematologic abnormalities at Week 48 according to NCI-CTCAE

Timeframe: At Week 48

Part D: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities at Week 36 according to NCI-CTCAE

Timeframe: At Week 36

Part D: Number of participants with Grade 3 and Grade 4 clinical chemistry abnormalities at Week 48 according to NCI-CTCAE

Timeframe: At Week 48

Secondary outcomes:

Part A: Serum concentration of Efimosfermin on Day 8

Timeframe: Pre-dose on Day 8

Part A: Observed concentration of Efimosfermin at the end of the dosing interval (Ctrough)

Timeframe: Pre-dose on Days 29, 57, 85 and 113

Part B: Serum concentration of Efimosfermin on Day 7

Timeframe: Pre-dose on Day 7

Part B: Observed concentration of Efimosfermin at the end of the dosing interval (Ctrough)

Timeframe: Pre-dose on Days 29, 57, 85, 113, 141, 169 and 197

Part B: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC [0-tau]) of Efimosfermin

Timeframe: Pre-dose on Days 29, 57, 85, 113, 141, 169 and 197

Part C: Observed concentration of Efimosfermin at the end of the dosing interval (Ctrough)

Timeframe: Pre-dose on Study Days 197, 225, 253, 281, 309, 337, 365 and 393

Part C: Area Under the Concentration-Time Curve Over the Dosing Interval at Steady State (AUC [0-tau]) of Efimosfermin

Timeframe: Pre-dose on Study Days 197, 225, 253, 281, 309, 337, 365 and 393

Interventions:
Drug: Efimosfermin
Drug: Placebo
Enrollment:
231
Primary completion date:
2025-27-10
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Nonalcoholic Steatohepatitis (NASH)
Product
Not applicable
Collaborators
Not applicable
Study date(s)
September 2021 to October 2025
Type
Interventional
Phase
2

Participation criteria

Sex
Female & Male
Age
18 - 75 Years
Accepts healthy volunteers
No
  • Inclusion Criteria (Part A and Part B):
  • Participant is either male or female and 18 to 75 years of age inclusive, at the time of signing the informed consent

Trial location(s)

Location
Status
Contact us
Contact us
Location
QLMC
Tucson, Arizona, United States, 85712
Status
Study Complete
Location
Lovelace
Albuquerque, New Mexico, United States, 87108
Status
Terminated/Withdrawn
Location
Olympus Family Medicine
Salt Lake City, Utah, United States, 84117
Status
Study Complete
Location
South Ogden Family Medicine
South Ogden, Utah, United States, 84405
Status
Study Complete
Location
Panex Clinical Research
Miami Lakes, Florida, United States, 33014
Status
Study Complete
Location
Catalina Research Institute
Montclair, California, United States, 91763
Status
Study Complete
Location
Southwest General Healthcare Center
Fort Myers, Florida, United States, 33907
Status
Study Complete
Location
Lillestol Research LLC
Fargo, North Dakota, United States, 58104
Status
Study Complete
Location
Accelemed Research
Austin, Texas, United States, 78745
Status
Study Complete
Location
Galenus Group
Lehigh Acres, Florida, United States, 33976
Status
Study Complete
Location
Central Research Associates
Birmingham, Alabama, United States, 35205
Status
Study Complete
Location
Liver Institute NorthWest
Seattle, Washington, United States, 98105
Status
Study Complete
Location
Century Research
Miami, Florida, United States, 33173
Status
Study Complete
Location
Liver Specialist of Texas
Houston, Texas, United States, 77030
Status
Terminated/Withdrawn
Location
Arizona Liver Health
Chandler, Arizona, United States, 85224
Status
Study Complete
Location
American Research Corporation at Texas Liver Institute
San Antonio, Texas, United States, 78215
Status
Study Complete
Location
Advanced Clinical Research
Miami, Florida, United States, 33156
Status
Study Complete
Location
Liver Institute PPLC
Tucson, Arizona, United States, 85712
Status
Study Complete
Location
Miami Clinical Research
Miami, Florida, United States, 33155
Status
Study Complete
Location
Velocity Clinical Research
East Greenwich, Rhode Island, United States, 02818
Status
Study Complete
Location
Tandem Clinical Research
Marrero, Louisiana, United States, 70072
Status
Study Complete
Location
Great Lakes Gastroenterology
Mentor, Ohio, United States, 44060
Status
Terminated/Withdrawn
Location
Houston Research Institute
Houston, Texas, United States, 77079
Status
Study Complete
Location
Kansas City Research Institute
Kansas City, Missouri, United States, 64131
Status
Study Complete
Location
Pinnacle Clinical Research – Austin
Austin, Texas, United States, 78757
Status
Study Complete
Location
Pinnacle Clinical Research – San Antonio
San Antonio, Texas, United States, 78229
Status
Study Complete
Location
South Texas Research Institute-Edinburg
Edinburg, Texas, United States, 75839
Status
Study Complete
Location
IMA Clinical Research
Warren, New Jersey, United States, 07059
Status
Terminated/Withdrawn
Location
Gastroenterologist of Greater Orlando
Orange City, Florida, United States, 32763
Status
Terminated/Withdrawn
Location
Apex Mobile Clinical Research
Bellaire, Texas, United States, 77401
Status
Study Complete
Location
Arizona Liver Health
Peoria, Arizona, United States, 85381
Status
Study Complete
Location
Arizona Liver Health
Tucson, Arizona, United States, 85712
Status
Study Complete
Location
Coastal Research Institute, LLC
Fayetteville, North Carolina, United States, 28304
Status
Study Complete
Location
LA Universal
Los Angeles, California, United States, 90057
Status
Terminated/Withdrawn
Location
Admed Research
Miami, Florida, United States, 33173
Status
Study Complete
Location
Eagle Clinical Research
Chicago, Illinois, United States, 60621
Status
Terminated/Withdrawn
Location
M3 Wake Research Associates
Raleigh, North Carolina, United States, 27612
Status
Terminated/Withdrawn
Location
Alliance Research Institute
Canoga Park, California, United States, 91304
Status
Study Complete
Location
Evolution Clinical Trials
Hialeah Gardens, Florida, United States, 33016
Status
Study Complete
Location
Quality Research, Inc
San Antonio, Texas, United States, 78209
Status
Study Complete
Location
South Texas Research Institute-Brownsville
Brownsville, Texas, United States, 78520
Status
Study Complete
Location
Fresno Clinical Research Center
Fresno, California, United States, 92720
Status
Study Complete
Location
Entrust Clinical Research Center
Kendall, Florida, United States, 33176
Status
Study Complete
Location
GI Associates & Endocsopy Center
Flowood, Mississippi, United States, 39232
Status
Terminated/Withdrawn
Location
Covenant Metabolic Specialists - Fort Myers
Fort Myers, Florida, United States, 33912
Status
Study Complete
Location
Covenant Metabolic Specialists - Sarasota
Sarasota, Florida, United States, 34240
Status
Study Complete
Location
G+C Research Group
Miami, Florida, United States, 33126
Status
Study Complete
Location
Inland Empire Clinical Trials
Rialto, California, United States, 92377
Status
Study Complete
Location
FOMAT Medical Research
Oxnard, California, United States, 93030
Status
Study Complete
Location
Velocity Clinical Research - Waco
Waco, Texas, United States, 76710
Status
Study Complete
Location
Ark Clinical Research
Fountain Valley, California, United States, 92708
Status
Study Complete
Location
LinQ Research, LLC
Pearland, Texas, United States, 77584
Status
Study Complete
Location
Texas Liver Institute - Austin
Austin, Texas, United States, 78757
Status
Study Complete
Location
Pinnacle Clinical Research - Georgetown
Georgetown, Texas, United States, 78626
Status
Study Complete
Location
Arizona Clinical Trials - Flagstaff
Flagstaff, Arizona, United States, 86001
Status
Terminated/Withdrawn
Location
Progressive Medical Research
Port Orange, Florida, United States, 32127
Status
Study Complete
Location
Charter Research
Orlando, Florida, United States, 32803
Status
Study Complete
Location
Knowledge Research Center
Orange, California, United States, 92868
Status
Study Complete
Location
California Liver Institute
Pasadena, California, United States, 91105
Status
Terminated/Withdrawn

Study documents

Protocol
Available language(s): English
Statistical analysis plan
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Results posted on ClinicalTrials.gov

Recruitment status
Completed
Actual primary completion date
2025-27-10
Actual study completion date
2025-27-10

Plain language summaries

Summary of results in plain language
Available language(s): English, Spanish (United States)

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website